Stockreport

BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS

Brainstorm Cell Therapeutics Inc.  (BCLI) 
Last brainstorm cell therapeutics inc. earnings: 11/14 06:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.brainstorm-cell.com
PDF NEW YORK, Feb. 23, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative disea [Read more]